NCT04524442 2025-01-24Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsAdvanced Accelerator ApplicationsPhase 4 Completed42 enrolled 11 charts
NCT03817866 2022-12-20Chromogranin A as Blood Marker in Cancer PatientsBrahms AGCompleted175 enrolled
NCT01327612 2021-02-21Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)AmgenPhase 2 Completed12 enrolled 21 charts
NCT00869050 2016-07-25Capecitabine and Temozolomide for Neuroendocrine CancersColumbia UniversityPhase 2 Completed41 enrolled 9 charts